Persisting IL-18 levels after COVID-19 correlate with markers of cardiovascular inflammation reflecting potential risk of CVDs development

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ANDREJČINOVÁ Ivana BLAZKOVA Gabriela PAPATHEODOROU Ioanna BENDÍČKOVÁ Kamila BOSÁKOVÁ Veronika SKOTAKOVA Monika PANOVSKÝ Roman OPATŘIL Lukáš VYMAZAL Ondřej KOVAČOVICOVÁ Petra ŠRÁMEK Vladimír HELÁN Martin HORTOVÁ KOHOUTKOVÁ Marcela FRIČ Jan

Year of publication 2024
Type Article in Periodical
Magazine / Source Heliyon
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S2405844024019698?via%3Dihub
Doi http://dx.doi.org/10.1016/j.heliyon.2024.e25938
Keywords COVID-19; Inflammation; CVDs; COVID-19 long-term consequences; IL-18
Attached files
Description COVID-19 manifestation is associated with a strong immune system activation leading to inflammation and subsequently affecting the cardiovascular system. The objective of the study was to reveal possible interconnection between prolongated inflammation and the development or exacerbation of long-term cardiovascular complications after COVID-19. We investigated correlations between humoral and cellular immune system markers together with markers of cardiovascular inflammation/ dysfunction during COVID-19 onset and subsequent recovery. We analyzed 22 hospitalized patients with severe COVID-19 within three timepoints (acute, 1 and 6 months after COVID-19) in order to track the impact of COVID-19 on the long-term decline of the cardiovascular system fitness and eventual development of CVDs. Among the cytokines dysregulated during COVID-19 changes, we showed significant correlations of IL-18 as a key driver of several pathophysiological changes with markers of cardiovascular inflammation/dysfunction. Our findings established novel immune-related markers, which can be used for the stratification of patients at high risk of CVDs for further therapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.